Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

HIV Infections 4Acquired Immunodeficiency Syndrome 4Sarcoma, Kaposi 3Lymphoma 2Head and Neck Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Pancreatic Neoplasms 1Nervous System Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Hematologic Diseases 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 38Docetaxel 38palbociclib 36Carboplatin 32Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × Bleomycin × Clear all
NCT01872923 2014-06-16

Dose Escalating Study for Amphinex-based PCI of Bleomycin.

PCI Biotech AS

Phase 1 Completed
3 enrolled
BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡